XOMA's Acquisition of Royalty and Milestone Interest in Checkmate’s Vidutolimod from Kuros Biosciences
North America. North America Legal Chronicle. July 21, 2021

XOMA’s Acquisition of Royalty and Milestone Interest in Checkmate’s Vidutolimod from Kuros Biosciences

By Federica Tiefenthaler

Paul Hastings advised Xoma Corporation on the deal. Vischer advised Kuros Biosciences AG. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator, announced the acquisition of the royalty interest...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
North America. North America Legal Chronicle. March 29, 2021

XOMA and Viracta Therapeutics’ Multi-License Milestone and Royalty Monetization Transaction

By Martina Bellini

Paul Hastings LLP advised Xoma Corporation on the deal. Xoma Corporation, a biotechnology and pharmaceutical royalty aggregator announced its multi-license and milestone monetization transaction with Viracta Therapeutics....

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here